In 17 February 2016, the FDA granted Breakthrough Therapy designation for durvalumab (Imfinzi) human monoclonal antibody directed against PD-L1, for the treatment of patients with PD-L1-positive inoperable or metastatic urothelial bladder cancer whose tumor has progressed during or after one standard platinum-based regimen on the basis of early clinical data from a Phase I trial [77] (Table 6). The gene discussed is CD274; the disease is neoplasm.